Technological Innovation and Strengthening the R&D Platform
First written in FY2016. 26 of 45 entries say "Advanced", first in FY2017. Latest entry: FY2027-H1.
27 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥7,009 million.」
R&D expenses totaled ¥7,009 million, up from ¥6,741 million in the same period of the previous year. The expansion of investment in the R&D platform is shown in numerical terms. - 2026-11-12AdvancedResults presentation
「2026年4月に薬事申請、薬事審査が予定通り進行中」
ROH-101の薬事申請・審査の進行、ROH-201の第3相試験準備、ROH-001の第2相試験進行など、医療用パイプラインの具体的な進捗を示している。 - FY2026AdvancedAnnual report
「During the current consolidated fiscal year, the company also began a domestic Phase II clinical trial of the ophthalmic product ROH-001, which is intended to slow the progression of myopia. In the field of regenerative medicine, it began a domestic Phase II clinical trial of ADR-002K, a regenerative medicine product for heart failure caused by ischemic heart disease.」
Total R&D expenses reached ¥13,861 million, with clear progress in the development stages of the medical and regenerative medicine businesses through the start of domestic Phase II clinical trials for ROH-001 and ADR-002K. - FY2026-H1Decline in interim research and development expensesAnnual report
「Total R&D expense for the interim consolidated accounting period was ¥6,741 million.」
R&D expenses decreased from ¥8,143 million in the same period of the previous year to ¥6,741 million. Although the company continues to invest in R&D, investment in the most recent interim period was below the level of the same period of the previous year. - FY2025-H1AdvancedAnnual report
「Total R&D expense for the six-month interim consolidated accounting period was ¥8,143 million.」
The company disclosed R&D expenses of ¥8,143 million for the current interim consolidated accounting period, up from ¥5,663 million in the same period of the previous year. The company shows the expansion of R&D investment in specific monetary terms. - FY2024AdvancedAnnual report
「Total R&D expenses for the fiscal year were ¥13,461 million, after eliminating intersegment transactions,」
R&D expenses increased from ¥11,115 million in the previous fiscal year to ¥13,461 million. The company describes its research fields and specific achievements, including the start of a domestic Phase I clinical trial for the ophthalmic pharmaceutical ROH-001, regenerative medicine research, and joint research with universities and external research institutions. - FY2024-Q3AdvancedAnnual report
「Total R&D expense for the nine-month period ended the current third quarter was ¥8,420 million.」
R&D expenses for the cumulative third quarter totaled ¥8,420 million, up from ¥7,645 million in the same period of the previous year. The company shows the expansion of investment in its R&D platform in specific monetary terms. - FY2024-Q2AdvancedAnnual report
「Total R&D expense for the six-month period ended the current second quarter was ¥5,663 million.」
R&D expenses totaled ¥5,663 million, up from ¥5,376 million in the same period of the previous year. The company shows the expansion of investment in its R&D platform in specific monetary terms. - FY2024-Q1AdvancedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥2,507 million.」
First-quarter R&D expenses totaled ¥2,507 million, up from ¥2,250 million in the same period of the previous year. The company shows the expansion of investment in its R&D platform in specific monetary terms. - FY2023AdvancedAnnual report
「Total R&D expenses for the fiscal year were ¥11,115 million, after eliminating intersegment transactions, and R&D activities by segment were as follows.」
R&D expenses increased to ¥11,115 million, and the company is advancing collaboration with external research institutions and other companies and developing new products in areas including eye care, skincare, functional foods, diagnostic agents, ophthalmic pharmaceuticals, and regenerative medicine. - FY2023-Q3AdvancedAnnual report
「Total R&D expense for the nine-month period ended the current third quarter was ¥7,645 million.」
R&D expenses for the cumulative third quarter totaled ¥7,645 million, up from ¥6,222 million in the same period of the previous year. The company shows the expansion of R&D investment in specific monetary terms. - FY2023-Q2AdvancedAnnual report
「Total R&D expense for the six-month period ended the current second quarter was ¥5,376 million.」
R&D expenses totaled ¥5,376 million, up from ¥4,283 million in the same period of the previous year. - FY2023-Q1AdvancedAnnual report
「Total R&D expense for the three-month period ended the current first quarter was ¥2,250 million.」
The company disclosed first-quarter R&D expenses of ¥2,250 million, up from ¥1,894 million in the same period of the previous year. - FY2022-Q3AdvancedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥6,222 million.」
The company disclosed R&D expenses of ¥6,222 million for the cumulative third quarter, up from ¥5,717 million in the cumulative third quarter of the previous fiscal year, indicating an increase in R&D investment. - FY2022-Q2RestatedAnnual report
「Total R&D expense for the six-month period ended the current second quarter was ¥4,283 million.」
The company cites R&D expenses of ¥4,283 million for the cumulative second quarter as evidence of continued investment in its R&D platform. - FY2022-Q1RestatedAnnual report
「Total R&D expense for the three-month period ended the current first quarter was ¥1,894 million.」
The company cites R&D expenses of ¥1,894 million for the cumulative first quarter as evidence of continued investment in R&D. - FY2021AdvancedAnnual report
「Total R&D expenses for the fiscal year were ¥7,944 million, after eliminating intersegment transactions,」
R&D expenses totaled ¥7,944 million, up from ¥7,082 million in the previous fiscal year. The company is expanding its research fields to include ophthalmic pharmaceuticals, regenerative medicine using stem cells, functional foods, and collaboration with external research institutions. - FY2021-Q3AdvancedAnnual report
「Total R&D expense for the nine-month period ended the current third quarter was ¥5,717 million.」
The company disclosed R&D expenses of ¥5,717 million for the cumulative third quarter, up from ¥4,992 million in the same period of the previous year, indicating an increase in R&D investment. - FY2021-Q2RestatedAnnual report
「Total R&D expense for the six-month period ended the current second quarter was ¥3,495 million.」
The company disclosed R&D expenses of ¥3,495 million for the cumulative second quarter, reaffirming its continued investment in R&D. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥1.694 billion.」
The company reaffirms its continued investment in R&D, citing ¥1,694 million in R&D expenses for the cumulative first quarter. - FY2020AdvancedAnnual report
「Total R&D expenses for the fiscal year were ¥7,082 million, after eliminating intersegment transactions,」
R&D expenses totaled ¥7,082 million for the full year, and the company is advancing R&D in areas including collaboration with universities and other external institutions, advanced technologies, regenerative medicine, and food products and supplements. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥4.992 billion.」
The company disclosed R&D expenses of ¥4,992 million for the cumulative third quarter, reaffirming its continued investment in R&D. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥3.369 billion.」
The company disclosed R&D expenses of ¥3,369 million for the cumulative second quarter, reaffirming its continued investment in R&D. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥1.661 billion.」
The company disclosed R&D expenses of ¥1,661 million for the first quarter, reaffirming its continued investment in its R&D platform. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥4.941 billion.」
The company reaffirms its continued investment in R&D, citing R&D expenses of ¥4,941 million for the cumulative third quarter. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥3.341 billion.」
The company reports R&D expenses of ¥3,341 million for the cumulative second quarter, reaffirming its continued investment in R&D. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥1.652 billion.」
The company cites R&D expenses of ¥1,652 million for the cumulative first quarter as evidence of continued investment in R&D. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥4.838 billion.」
The company reports R&D expenses of ¥4,838 million for the cumulative third quarter, reaffirming its continued investment in its R&D platform. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥3.238 billion.」
The company cites R&D expenses of ¥3,238 million for the cumulative second quarter as evidence of continued investment in R&D. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥1.5 billion.」
The company cites R&D expenses of ¥1,500 million for the cumulative first quarter as evidence of continued investment in R&D. - FY2017AdvancedAnnual report
「Total R&D expenses for the fiscal year were ¥6,146 million, after eliminating intersegment transactions, and R&D activities by segment were as follows.」
The company recorded R&D expenses of ¥6,146 million and is also pursuing joint research with universities and other institutions in Japan and overseas, as well as the integration of advanced technologies. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥4,344 million.」
The company cites R&D expenses of ¥4,344 million for the cumulative third quarter as evidence of continued investment in R&D. - FY2017-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥2,926 million.」
The company cites R&D expenses of ¥2,926 million for the cumulative second quarter as evidence of continued investment in its R&D platform. - FY2016First statedAnnual report
「The company considers superiority in development capabilities and technology to be the key factor, and is actively promoting the establishment of an integrated research structure by focusing on technological innovation and strengthening its research base, while pursuing joint research with venture companies and researchers in Japan and overseas.」
The company positions technological capabilities as an important competitive factor and cites technological innovation, strengthening its research base, and joint research with venture companies and researchers as means of developing its research structure.